Misleading Reporting of a Negative Randomized Clinical Trial May Affect Clinical Practice
P
Paul de Boissieu
(Paul de Boissieu, MD, PhD, Clinical Research Department, Paris Saint-Joseph Hospital Group, Paris, France; and Sylvie Chevret, MD, PhD, ECSTRRA, UMR 1342, Inserm, Paris Cité Université, Paris, France)
S
Sylvie Chevret
Article Details
Journal
Journal of Clinical Oncology
Volume / Issue
Vol. 43, Issue 3
Published
January 20, 2025
Pages
354-355
ISSN
0732-183X
Publisher
Lippincott Williams & Wilkins
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
ISSN: 0732-183X Health Sciences
Authors (2)
P
Paul de Boissieu
Paul de Boissieu, MD, PhD, Clinical Research Department, Paris Saint-Joseph Hospital Group, Paris, France; and Sylvie Chevret, MD, PhD, ECSTRRA, UMR 1342, Inserm, Paris Cité Université, Paris, France
S
Sylvie Chevret
Related Articles from this Journal
Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer
Ismaela Anna Vascotto, Filippo Antonica et al.
Aug 2026
10.1200/jco-26-00658
Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial
Samer A. Srour, Jad Chahoud et al.
Aug 2026
10.1200/jco-26-00388
Adjuvant Carboplatin for Early-Stage, Triple-Negative Breast Cancer: Taxane and Patient Selection
Risako Komata, Kenju Ando et al.
Aug 2026
10.1200/jco-26-00140
Erratum: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE)
Ghayas C. Issa, Branko Cuglievan et al.
Aug 2026
10.1200/jco-26-01743
Reply to: Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer
Irbaz Bin Riaz, R. Bryan Rumble et al.
Aug 2026
10.1200/jco-26-01001